Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: First clinical experience
Florian Eichhorn, Laura V. Klotz, Mark Kriegsmann, Helge Bischoff, Marc A. Schneider, Thomas Muley, Katharina Kriegsmann, Uwe Haberkorn, Claus Peter Heußel, Rajkumar Savai, Inka Zoernig, Dirk Jaeger, Michael Thomas, Hans Hoffmann, H. Winter, Martin Eichhorn
Topics & Concepts
MedicinePembrolizumabLung cancerAdenocarcinomaNeoadjuvant therapyOncologyInternal medicineImmunotherapyRadiologyCarcinomaCancerSurgeryBreast cancerCancer Immunotherapy and BiomarkersLung Cancer Diagnosis and TreatmentCancer Research and Treatments